Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Harga Amgen saat ini di pasar adalah Rp 7.100.825,32, dengan volume perdagangan 24 jam sebesar Rp 15,81T. Kapitalisasi pasar aset ini adalah Rp 3,83P, setelah bergerak 4.32% dalam satu hari terakhir.
Amgen tertokenisasi diperdagangkan di Rp 7.189.844,5, dengan kapitalisasi pasar tertokenisasi sebesar Rp 71,6M dan volume perdagangan 24 jam sebesar Rp 15,38B. Aset tertokenisasi ini telah bergerak 15.40% dalam 24 jam terakhir.